Creso’s launch of cannaQIX® tea products opens up new opportunities
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Creso Pharma Limited (ASX:CPH; FRA:1X8) has launched its proprietary CBD-based teas products in Switzerland with other European markets, including Germany, earmarked for near-term expansion.
Three new products have been launched under the cannaQIX® brand and include cannaQIX® tea, cannaQIX® NITE tea and cannaQIX® Immunity tea.
While the additional revenue streams generated by the launch of these products will be important for Creso Pharma, it will also assist in promoting the broader cannaQIX® brand.
Creso has a proven track record for successful product development and commercialisation, with its cannaQIX® brand of products now available in Switzerland and several European countries.
The three new teas as illustrated below have been developed based on a new second generation innovative technology that optimises the CBD content in compliance with regulations and allows for a better taste.
Features of new products
The development of the new tea products is a groundbreaking technological achievement for Creso Pharma and provides the company with a significant competitive advantage.
Creso will now progress the use of the new technology in the manufacturing of its cannaQIX® lozenge flagship products.
Looking specifically at the three different products, cannaQIX® tea is designed to help the management of stress, supporting a better quality of life, while cannaQIX® NITE tea should be consumed at night with a view to providing a better night’s sleep.
The cannaQIX® Immunity tea provides supplements and taste to optimise well-being.
Having completed the necessary legal and regulatory due diligence, the new tea products can now be legally marketed and sold throughout Switzerland, leveraging Creso’s established distribution network comprised of over 2,100 points of sales across Switzerland where Creso’s cannaQIX® products are already being sold.
These include pharmacies, pharmacy networks, drugstores, health nutrition shops and large retail groups including leading department store chain Manor.
Creso also supplies all major wholesalers in the country including Galexis, Amedis and Voigt.
This provides the company with an established footprint, significantly de-risking the launch of each new product it brings to market.
Commenting on the launch of the new products and the scope for taking advantage of associated opportunities, commercial and development director Doctor Gian Trepp said, “We are proud to have completed the finalisation of this ground-breaking technology for our new CBD tea products, which opens a number of new and globally applicable opportunities for Creso Pharma.
"The new products and formulation provide a very tasty CBD tea that will become a key component in the future production of the cannaQIX® lozenges.
"We look forward to providing further updates on future product additions and our European expansion initiatives.”
Proposed launch of hemp tea products in Germany
Management will also look to launch its new hemp tea products in Germany following a recent decision by the German Federal Court of Justice to annul previous charges against hemp tea sellers which had temporarily delayed the scheduled rollout of the company’s hemp tea products in the September quarter of 2020.
The favourable decision has removed ambiguity over the guidelines concerning the sale of food products based on hemp flowers and leaves in Germany, leaving Creso well-positioned to actively market and sell its hemp tea products in that jurisdiction without any further regulatory approvals or hurdles to overcome.
Upon successful rollout of its new products in Switzerland and Germany, Creso will explore the opportunity to expand the distribution of its hemp tea products into other European companies, and in line with its standard practices, the group will undertake the necessary due diligence to confirm the legality of the sale of its products in each new jurisdiction as required.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
